Frederick G Vogt insider trades: Iovance Biotherapeutics (IOVA) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Frederick reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 14, 2025 | IOVA | ↑ Buy | 25,000 | $1.69 | $42K | Direct | May 16, 2025 (2d) |
| Nov 28, 2022 | IOVA | ↑ Buy | 1,000 | $5.98 | $6K | Direct | Nov 28, 2022 (0d) |
| Jun 1, 2022 | IOVA | ↑ Buy | 1,000 | $6.44 | $6K | Direct | Jun 2, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Frederick G Vogt's insider trades
Frederick G Vogt is Interim CEO & General Counsel at Iovance Biotherapeutics (IOVA). Since Jun 1, 2022, Frederick has reported 3 open-market purchases worth $55K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include option exercises (22 filings), shares withheld for taxes (22 filings), grants and awards (9 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IOVA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.